Thera-SAbDab

NARLUMOSBART

> Structural Summary

Therapeutic	Narlumosbart
Target	TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF
Heavy Chain	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS
Light Chain	EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (Feb '25)	Phase-III
Estimated Status (Feb '25)	Approved
Recorded Developmental Technology
INN Year Proposed	2022
INN Year Recommended	2023
Companies Involved	CSPC Pharmaceutical Group, Shanghai Jinmante Biotechnology
Conditions Approved	Giant cell tumour of bone
Conditions Active	Hypercalcemia of malignancy, Glucocorticoid-induced osteoporosis, Bone metastases from solid tumours
Conditions Discontinued	Malignant hypercalcaemia
Notes	6ghg is technically within 95% ID; but CDRH3 length 7 vs length 15. Same Fv sequence as Denosumab.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy